The effect of vitamin D on the regression of human papilloma virus infection and metabolic parameters: a retrospective study

Purpose: Human papillomavirus (HPV) is the primary cause of cervi- cal cancer. Ourstudy aimstoevaluate theeffects ofvitamin Don HPV regression, related cytologicalpathologiesandvariousmetabolicparameters. Materials and methods: 100 high-risk HPV positive patients, who were detected from hospital database, were divided into 2 groups as those who received vitamin D supplements (n = 50) and did not receive vitamin D supplements (n = 50). We determined the changesinserumvitamin Dconcentrations, metabolicparametersof patients and regression of HPV a ter 6 months. Then, we compared the results of patients who took vitamin D supplements, and those who did not. Results: Patient characteristics of both groups were similar in terms of smoking, using oral contraceptives, operation status, body mass index, and mean age of first coitus. Considering the findings ofour study, the difference in rate of HPV regression was not significant in the group with a history of vitamin D use (P = 0.804). Regarding metabolic parameters, we observed significant decrease in insulin (P < 0.001), triglyceride (P = 0.019), and CRP (P < 0.001) levels in the group witha history ofvitamin D use. Conclusion: According to our findings, vitamin D supplementation does not significantly increase the rate of HPV regression. On the other hand, its metabolic effects are noteworthy. It has positive effects on glucose homeostasis and lipid profile. In the light ofprevious studies, vitamin D may be helpful in the treatment of vaginal infections, nonetheless it is not a as effective concerning cervical HPV infections.

Human papillomavirus; Pap smear; Vitamin D

[1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136: E359–E386.

[2] Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890–907.

[3] Eun TJ, Perkins RB. Screening for Cervical Cancer. Medical Clinics of North America. 2020; 104: 1063–1078.

[4] Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. The Lancet Oncology. 2005; 6: 204.

[5] Landy R, Pesola F, Castañón A, Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stagespecific results from a nested case-control study. British Journal of Cancer. 2016; 115: 1140–1146.

[6] Shiko Y, Konno R, Konishi H, Sauvaget C, Ohashi Y, Kakizoe T. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women. BMC Infectious Diseases. 2020; 20: 808.

[7] Penaranda EK, Shokar N, Ortiz M. Relationship between metabolic syndrome and history of cervical cancer among a us national population. ISRN Oncology. 2013; 2013: 840964.

[8] Molokwu JC, Penaranda E, Lopez DS, Dwivedi A, Dodoo C, Shokar N. Association of metabolic syndrome and human papillomavirus infection in men and women residing in the United States. Cancer Epidemiology, Biomarkers & Prevention. 2018; 26: 1321–1327.

[9] Ahn HK, Shin JW, Ahn HY, Park C, Lee NW, Lee JK, et al. Metabolic components and recurrence in early-stage cervical cancer. Tumour Biology. 2015; 36: 2201–2207.

[10] Ulmer H, Bjørge T, Concin H, Lukanova A, Manjer J, Hallmans G, et al. Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can). Gynecologic Oncology. 2012; 125: 330–335.

[11] Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. British Journal of Cancer. 2009; 101: 1202–1206.

[12] Karamali M, Nourgostar S, Zamani A, Vahedpoor Z, Asemi Z. The favourable effects of long-term selenium supplementation on regression of cervical tissues and metabolic profiles of patients with cervical intraepithelial neoplasia: a randomised, double-blind, placebo-controlled trial. British Journal of Nutrition. 2015; 114: 2039–2045.

[13] Baker R, Dauner JG, Rodriguez AC, Williams MC, Kemp TJ, Hildesheim A, et al. Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infec- tion. Cytokine. 2011; 53: 282–285.

[14] Hosono S, Matsuo K, Kajiyama H, Hirose K, Suzuki T, Kawase T, et al. Association between dietary calcium and vitamin D intake and cervical carcinogenesis among Japanese women. European Journal of Clinical Nutrition. 2010; 64: 400–409.

[15] Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature Reviews. Cancer. 2007; 7: 684–700.

[16] Miettinen S, Ahonen MH, Lou Y, Manninen T, Tuohimaa P, Syvälä H, et al. Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. International Journal of Cancer. 2004; 108: 367–373.

[17] Vahedpoor Z, Jamilian M, Bahmani F, Aghadavod E, Karamali M, Kashanian M, et al. Effects of long-term vitamin D supplementation on regression and metabolic status of cervical intraepithelial neoplasia: a randomized, double-blind, placebo-controlled trial. Hormones & Cancer. 2017; 8: 58–67.

[18] Anastasi E, Filardi T, Tartaglione S, Lenzi A, Angeloni A, Morano S. Linking type 2 diabetes and gynecological cancer: an introductory overview. Clinical Chemistry and Laboratory Medicine. 2018; 56: 1413–1425.

[19] Kuo H, Lin Z, Kuo R, Shau W, Lai C, Yang Y, et al. The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia. The Oncologist. 2016; 20: 1051–1057.

[20] Jiamset I, Hanprasertpong J. Impact of diabetes mellitus on oncological outcomes after radical hysterectomy for early stage cervical cancer. Journal of Gynecologic Oncology. 2016; 27: e28.

[21] Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiology, Biomarkers & Prevention. 2006; 15: 1427–1437.

[22] Friedrich M, Villena-Heinsen C, Axt-Fliedner R, Meyberg R, Tilgen W, Schmidt W, et al. Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in cervical tissue. Anticancer Research. 2002; 22: 183–186.

[23] Deuster E, Jeschke U, Ye Y, Mahner S, Czogalla B. Vitamin D and VDR in gynecological cancers-a systematic review. International Journal of Molecular Sciences. 2018; 18: 8.

[24] García-Carrasco M, Mendoza-Pinto C, Munguía-Realpozo P, Rodríguez-Gallegos A, Vallejo-Ruiz V, Muñoz-Guarneros M, et al. Lack of association between serum 25-hydroxyvitamin D levels and cervical human papillomavirus infection in systemic lupus erythematosus. Lupus. 2015; 24: 606–612.

[25] Schulte-Uebbing C, Schlett S, Craiut I, Antal L, Olah H. Chronical cervical infections and dysplasia (CIN I, CIN II): Vaginal vitamin D (high dose) treatment: a new effective method? Dermatoendocrinology. 2014; 6: e27791.

[26] Koshiyama M. The effects of the dietary and nutrient intake on gynecologic cancers. Healthcare. 2019; 7.

[27] Asemi Z, Hashemi T, Karamali M, Samimi M, Esmaillzadeh A. Effects of vitamin D supplementation on glucose metabolism, lipid concentrations, inflammation, and oxidative stress in gestational diabetes: a double-blind randomized controlled clinical trial. American Journal of Clinical Nutrition. 2014; 98: 1425–1432.

[28] Javed A, Vella A, Balagopal PB, Fischer PR, Weaver AL, Piccinini F, et al. Cholecalciferol supplementation does not influence β-cell function and insulin action in obese adolescents: a prospective double-blind randomized trial. Journal of Nutrition. 2015; 145: 284–290.

[29] Chandler PD, Scott JB, Drake BF, Ng K, Manson JE, Rifai N, et al. Impact of vitamin D supplementation on inflammatory markers in African Americans: results of a four-arm, randomized, placebocontrolled trial. Cancer Prevention Research. 2014; 7: 218–225.

[30] Alpdemir M, Alpdemir MF. Vitamin D deficiency status in Turkey: a meta-analysis. International Journal of Medical Biochemistry. 2019; 2: 118–131.

[31] Hekimsoy Z, Dinç G, Kafesçiler S, Onur E, Güvenç Y, Pala T, et al. Vitamin D status among adults in the Aegean region of Turkey. BMC Public Health. 2010; 10: 782.